Trials / Unknown
UnknownNCT04933825
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
An Exploratory,Open-label,and Single Center Study to Evaluate the Safety and Efficacy of ET-02 in Patients With Relapsed or Refractory B-cell Malignancies(NHL/ALL).
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- EdiGene (GuangZhou) Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ET-02 | A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection. |
Timeline
- Start date
- 2021-07-20
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2021-06-22
- Last updated
- 2023-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04933825. Inclusion in this directory is not an endorsement.